Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Ovarian
Descriptor: HGF/SF expression


Reference Number: 301
Wong AS, Roskelley CD, Pelech S, Miller D, Leung PC, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res. 299, 248-56 (2004)
PubMed link      E-mail link

Reference Number: 322
Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, Kose MF, Ayhan A. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Cynecol Cancer 14, 152-6 (2004)
PubMed link      E-mail link

Reference Number: 323
Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, Kose MF, Ayhan A. Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 13, 771-5 (2003)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 401
Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 147, 2557-66. Epub 2006 Feb 9. (2006)
PubMed link      E-mail link

Reference Number: 437
Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer.  41, 555-63(2005)
PubMed link      E-mail link

Reference Number: 500
Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, Di Cunto F, Calogero R, Di Renzo MF. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Mol Cancer Ther. 5, 1126-35 (2006)
PubMed link      E-mail link

Reference Number: 554
Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res. 13, 2191-8 (2007)
PubMed link      E-mail link

Reference Number: 635
Zhou HY, Pon YL, Wong AS. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology. 148, 5195-208 (2007)
PubMed link      E-mail link

Reference Number: 842
Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong L, Yang P. Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken). 293, 1134-9 (2010)
PubMed link      E-mail link

Reference Number: 845
Wei W, Kong B, Yang Q, Qu X. Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1. Cancer Biol Ther. 9, 79-87 (2010)
PubMed link      E-mail link

Reference Number: 992
Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE, Stunes AK, Syversen U. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol. 121, 402-6 (2011)
PubMed link      E-mail link

Reference Number: 1032
Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Høgdall E, Kjær SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Høgdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA; Ovarian Cancer Association Consortium. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 20, 1638-48 (2011)
PubMed link      E-mail link

Reference Number: 1143
Wei W, Kong B, Qu X. Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features. J Obstet Gynaecol Res. 38, 57-64 (2012)
PubMed link      E-mail link

Reference Number: 1645
Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene 34, 144-53 (2015)
PubMed link      E-mail link

Reference Number: 1695
Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S, Ferlini C. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 5, 4855-67 (2014)
PubMed link      E-mail link

Reference Number: 1864
Nakamura M, Ono YJ, Kanemura M, Tanaka T, Hayashi M, Terai Y, Ohmichi M. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol Oncol. 139, 345-54 (2015)
PubMed link      E-mail link

Reference Number: 1870
Nakamura M, Ono YJ, Kanemura M, Tanaka T, Hayashi M, Terai Y, Ohmichi M. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol Oncol. 139, 345-54 (2015)
PubMed link      E-mail link